2008至2016年美国女性高级别宫颈病变估计病例数
CDC利用HPV-IMPACT基于人群的监测数据,分析2008–2016年≥18岁女性CIN2+率,并外推至全美估计病例数。2008年估计216,000例,2016年196,000例;18–29岁占比由55%降至36%,约76%病例归因于疫苗所覆盖HPV型别。
要点
- 2008至2016年美国女性CIN2+估计病例数由216,000降至196,000。
- 18–19岁和20–24岁女性CIN2+率显著下降,40–64岁显著上升。
- 约76%的CIN2+病例归因于美国现用疫苗覆盖的HPV型别。
核心结论
- 2008至2016年美国女性CIN2+估计病例数从216,000例降至196,000例,年轻女性占比明显下降。
- 约76%的CIN2+病例归因于美国现用HPV疫苗覆盖的型别。
研究设计与样本
- 基于HPV-IMPACT人群监测系统分析2008–2016年≥18岁女性CIN2+率,并按年龄别率外推全美估计病例数。
主要发现
- 2008年估计216,000例(95%CI 194,000–241,000),其中55%为18–29岁女性。
- 2016年估计196,000例(95%CI 176,000–221,000),其中36%为18–29岁女性。
- 2008至2016年,18–19岁和20–24岁女性CIN2+每10万女性率显著下降,40–64岁女性显著上升。
- 2008和2016年合计约76%的CIN2+病例归因于美国现用疫苗覆盖的HPV型别。
临床怎么用
- 应提高11或12岁女性常规HPV疫苗接种覆盖率,并推进至26岁的补种接种以进一步减少宫颈癌前病变。
- 解读CIN2+估计数变化时需考虑筛查和管理建议更新对检出率的影响。
局限性
- CIN2+估计数可能反映筛查和管理建议更新带来的检出变化,以及HPV疫苗一级预防的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human papillomavirus (HPV) causes approximately 30,000 cancers in the United States annually (1). HPV vaccination was introduced in 2006 to prevent HPV-associated cancers and diseases (1). Cervical cancer is the most common HPV-associated cancer in women (1). Whereas HPV-associated cancers typically take decades to develop, screen-detected high-grade cervical lesions (cervical intraepithelial neoplasia grades 2 [CIN2], 3 [CIN3], and adenocarcinoma in situ, collectively CIN2+) develop within a few years after infection and have been used to monitor HPV vaccine impact (1-3). CDC analyzed data from the Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT), a population-based CIN2+ surveillance system, to describe rates of CIN2+ among women aged ≥18 years during 2008-2016. Age-specific rates were applied to U.S. population data to estimate the total number of CIN2+ cases diagnosed in the United States in 2008* and in 2016. From 2008 to 2016, the rate of CIN2+ per 100,000 women declined significantly in women aged 18-19 years and 20-24 years and increased significantly in women aged 40-64 years. In the United States in 2008, an estimated 216,000 (95% confidence interval [CI] = 194,000-241,000) CIN2+ cases were diagnosed, 55% of which were in women aged 18-29 years; in 2016, an estimated 196,000 (95% CI = 176,000-221,000) CIN2+ cases were diagnosed, 36% of which were in women aged 18-29 years. During 2008 and 2016, an estimated 76% of CIN2+ cases were attributable to HPV types targeted by the vaccine currently used in the United States. These estimates of CIN2+ cases likely reflect changes in CIN2+ detection resulting from updated cervical cancer screening and management recommendations, as well as primary prevention through HPV vaccination. Increasing coverage of HPV vaccination in females at the routine age of 11 or 12 years and catch-up vaccination through age 26 years will contribute to further reduction in cervical precancers.
引用
- McClung NM, Gargano JW, Park IU, et al. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019. PMID: 30998672. doi:10.15585/mmwr.mm6815a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。